Journal of Kidney Cancer and VHL最新文献_第7页

Delayed Cardiac Metastasis from Renal Cell Carcinoma Caused by VHL Mutation. 肾细胞癌VHL突变致延迟性心脏转移。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2023-01-01 DOI: 10.15586/jkcvhl.v10i1.258

Christopher L Sudduth, Anthony Castagno, Peter Maggs

引用次数: 1

A Case Report: Mucinous Tubular and Spindle Cell Carcinoma of Kidney with Spindle Cell Predominance Mimicking Mesenchymal Tumour. 肾黏液管状和梭形细胞癌1例，梭形细胞为主，模拟间充质肿瘤。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-10-31 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i4.203

Natarajan Ramya, Murhekar Kanchan, Raja Anand, Sundersingh Shirley

{"title":"A Case Report: Mucinous Tubular and Spindle Cell Carcinoma of Kidney with Spindle Cell Predominance Mimicking Mesenchymal Tumour.","authors":"Natarajan Ramya, Murhekar Kanchan, Raja Anand, Sundersingh Shirley","doi":"10.15586/jkcvhl.v9i4.203","DOIUrl":"https://doi.org/10.15586/jkcvhl.v9i4.203","url":null,"abstract":"Mucinous tubular and spindle cell carcinoma (MTSCC) of kidney is a rare variant of renal cell carcinoma which was first described in the 2004 World Health Organization classification of tumours of the kidney. Morphologically, MTSCC is composed of tubules merging with bland-appearing spindle cells in a myxoid/mucinous stroma. Diverse morphological patterns have been reported in MTSCC; however, a spindle cell predominant morphology mimicking a mesenchymal tumour is rare and only two cases have been reported so far. We report a case of MTSCC with spindle cell predominance in kidney which was a diagnostic challenge. Though MTSCC usually shows an indolent course, there have been cases showing aggressive behaviour even with bland morphology. Hence, a thorough histopathological evaluation with ancillary studies are required to differentiate spindle cell predominant MTSCC from its mimics. Our case was a 40-year-old female who was incidentally found to have a well-defined hypodense lesion measuring around 2 cm in the upper pole of the right kidney. Right partial nephrectomy was performed which showed a 2.7 × 2.5 × 2 cm well-defined grey tan tumour without necrosis or haemorrhage, limited to kidney. Histopathological examination showed sheets of bland-appearing spindle cells mimicking a mesenchymal tumour. The tumour was extensively sampled, revealing small foci of tubule formation and mucinous stroma. Tumour cells were positive for CK7, AMACR, and PAX8. A final diagnosis of MTSCC was made. Hereby, we discuss ways of differentiating MTSCC from other spindle cell tumours of the kidney.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":" ","pages":"10-13"},"PeriodicalIF":1.6,"publicationDate":"2022-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9634216/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40468529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Mucinous Tubular and Spindle Cell Renal Cell Carcinoma (MTSC-RCC) with an Unusual Presentation in a Child. 儿童肾管状和梭形黏液细胞癌(MTSC-RCC)的不寻常表现。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-10-29 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i4.223

Kanika Sharma, Anjan Dhua, Sandeep Agarwala, Seema Kaushal

引用次数: 1

Partial Nephrectomy for T1b/T2 Renal Mass: An Added Shift from Radical Nephrectomy. 部分肾切除术治疗T1b/T2肾肿块:与根治性肾切除术相比的一个额外转移。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-10-06 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i4.255

Mohamed Sharafeldeen, Wael Sameh, Vahid Mehrnoush, Amer Alaref, Radu Rozenberg, Asmaa Ismail, Hazem Elmansy, Walid Shahrour, Ahmed Zakaria, Osama Elmeslemany, Nishigandha Burute, Anatoly Shuster, Owen Prowse, Ahmed Kotb

{"title":"Partial Nephrectomy for T1b/T2 Renal Mass: An Added Shift from Radical Nephrectomy.","authors":"Mohamed Sharafeldeen, Wael Sameh, Vahid Mehrnoush, Amer Alaref, Radu Rozenberg, Asmaa Ismail, Hazem Elmansy, Walid Shahrour, Ahmed Zakaria, Osama Elmeslemany, Nishigandha Burute, Anatoly Shuster, Owen Prowse, Ahmed Kotb","doi":"10.15586/jkcvhl.v9i4.255","DOIUrl":"https://doi.org/10.15586/jkcvhl.v9i4.255","url":null,"abstract":"The aim of our study was to show our short-term experience in managing large renal masses (cT1b/T2) through partial nephrectomy (PN) over the last 3 years. Retrospective data collection for all patients managed by PN for renal masses larger than 4 cm over the last 3 years. Epidemiological data were collected. Surgical data including surgical and ischemic times as well as intra and postoperative complications were collected. Pre- and postoperative estimated glomerular filtration rate (eGFR) data were collected and correlated as well as postoperative complications and recurrence. We could identify 47 patients managed by PN for radiologically confirmed >4 cm renal masses. The mean age of the patients was 55.7 ± 13.4, including 29 males and 18 females. Masses were T1b and T2 in 40 and 7 patients, respectively. The mean tumor size was 6.2 ± 1.5 cm. Using renal nephrometry score; 8, 28, and 11 had low, moderate, and high complexity, respectively. Renal cell carcinoma (RCC) was identified in 42 patients. Five patients out of 42 cancerous cases (12%) had pathological T3 RCC. The mean preoperative and postoperative eGFR were 89.09 ± 12.41 and 88.50 ± 10.50, respectively (P 0.2). The median follow-up was 14 months and within that short time, no patient had evidence for cancer recurrence. PN for large renal masses is safe in experienced hands and should be attempted in a higher percentage of patients, regardless of the tumor complexity. No cancer recurrence or deterioration of renal function was observed within our short-term follow-up.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":" ","pages":"1-5"},"PeriodicalIF":1.6,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40657815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma. 转移性肾细胞癌二线全身治疗的当前选择。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-09-29 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i3.243

Iraklis C Mitsogiannis, Maria Mitsogianni, Maria Papathanassiou, Maria Anagnostou, Ioannis Tamposis, Lampros Mitrakas, Maria Samara, Vassilios Tzortzis, Panagiotis J Vlachostergios

引用次数: 3

Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL. 了解贝尔祖替芬对VHL患者治疗策略的影响。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-09-28 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i3.245

Aileen Arevalo, Neal Patel, Peter Muraki, Shinji Ohtake, Gennady Bratslavsky, Chandra Clark, Joshua Mann, Othon Iliopoulos, Eric Jonasch, Ramaprasad Srinivasan, Brian Shuch

{"title":"Understanding the Impact of Belzutifan on Treatment Strategies for Patients with VHL.","authors":"Aileen Arevalo, Neal Patel, Peter Muraki, Shinji Ohtake, Gennady Bratslavsky, Chandra Clark, Joshua Mann, Othon Iliopoulos, Eric Jonasch, Ramaprasad Srinivasan, Brian Shuch","doi":"10.15586/jkcvhl.v9i3.245","DOIUrl":"https://doi.org/10.15586/jkcvhl.v9i3.245","url":null,"abstract":"Belzutifan was recently approved for the management of Von Hippel-Lindau disease (VHL). Given the morbidity of recurrent treatment, systemic therapy to reduce or eliminate the need for surgery has been long-awaited. Herein, we sought to gain insight about future utilization by surveying VHL kidney cancer experts in the United States. A survey developed by members of the VHL Alliance (VHLA) Clinical Advisory Council was distributed to kidney cancer providers at VHLA and National Comprehensive Cancer Network (NCCN) centers. Surveys were administered on a secure web-based platform. A total of 60 respondents from 29 institutions participated. Urologists (50%) and medical oncologists (43%) represented the majority of participants. The majority (98%) of respondents anticipated that belzutifan's approval would significantly change the current treatment landscape. Most reported that therapy should be continuous (76%). There was a difference in willingness to prescribe belzutifan by specialty (38% of urologists vs 91% of medical oncologists (P = 0.02)). In individuals with renal tumors <3 cm, 36% would still recommend surveillance, while 36% would initiate belzutifan to prevent growth. In those with multifocal renal lesions and growth of a solitary tumor on belzutifan, 50% would proceed with only treatment of that site. In conclusion, VHL kidney cancer specialists anticipate a paradigm shift with the approval of belzutifan. Provider roles may change with movement away from surgical management. Opinions on treatment indications, such as when to initiate therapy and how to best salvage, vary widely and therefore collaborative efforts among experts may assist in the development of new clinical guidelines.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":" ","pages":"41-46"},"PeriodicalIF":1.6,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9551368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40656249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Synchronized Laparoscopic Bilateral Adrenalectomy for Pheochromocytoma in Multiple Endocrine Neoplasia Syndrome: A Case Report. 同步腹腔镜双侧肾上腺切除术治疗多发性内分泌瘤综合征嗜铬细胞瘤1例。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-09-02 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i3.239

Ali Eslahi, Shahryar Zeighami, Faisal Ahmed, Seyed Hossein Hosseini, Bahareh Ebrahimi, Mohammad Hossein Anbardar

{"title":"Synchronized Laparoscopic Bilateral Adrenalectomy for Pheochromocytoma in Multiple Endocrine Neoplasia Syndrome: A Case Report.","authors":"Ali Eslahi, Shahryar Zeighami, Faisal Ahmed, Seyed Hossein Hosseini, Bahareh Ebrahimi, Mohammad Hossein Anbardar","doi":"10.15586/jkcvhl.v9i3.239","DOIUrl":"https://doi.org/10.15586/jkcvhl.v9i3.239","url":null,"abstract":"Pheochromocytomas are tumors producing catecholamines that arise from chromaffin cells in the adrenal medulla. They are usually benign in multiple endocrine neoplasia type 2 (MEN2) syndrome, but they tend to present bilaterally in 50-80% of the patients. Few researchers have reported success with simultaneous laparoscopic bilateral adrenalectomy. Hence, we report a 48-year-old woman who presented with a panic attack, headache, and abdominal discomfort that had started 10 years ago. The computed tomography (CT) scan showed a large bilateral cystic lesion in both adrenal glands in favor of pheochromocytomas (30 × 22 mm and 18 × 15 mm on the right side and 40 × 33 mm and 35 × 28 mm on the left side). The patient underwent bilateral laparoscopic adrenalectomy without intraoperative or postoperative complications. The total blood loss was 50 cc, and the operative time was 4 h. The histopathology of the specimen revealed pheochromocytomas of adrenal masses. In conclusion, our case demonstrates that synchronized laparoscopic bilateral adrenalectomy can be a safe and feasible treatment option for pheochromocytomas in MEN2 patients.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"9 3","pages":"24-28"},"PeriodicalIF":1.6,"publicationDate":"2022-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463070/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33467023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modern Management of Localized Renal Cell Carcinoma- Is Ablation Part of the Equation? 局部肾细胞癌的现代治疗——消融是治疗方法的一部分吗?

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-08-15 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i3.233

Zev Leopold, Rachel Passarelli, Mark Mikhail, Alexandra Tabakin, Kevin Chua, Ronald D Ennis, John Nosher, Eric A Singer

引用次数: 2

Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas. 侵袭脾胰的局部晚期肾细胞癌的成功手术治疗。

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-08-12 eCollection Date: 2022-01-01 DOI: 10.15586/jkcvhl.v9i3.231

Mohamed Sharafeldeen, Vahid Mehrnoush, Asmaa Ismail, Ahmed Zakaria, Hazem Elmansy, Walid Shahrour, Owen Prowse, Ahmed Kotb

{"title":"Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas.","authors":"Mohamed Sharafeldeen, Vahid Mehrnoush, Asmaa Ismail, Ahmed Zakaria, Hazem Elmansy, Walid Shahrour, Owen Prowse, Ahmed Kotb","doi":"10.15586/jkcvhl.v9i3.231","DOIUrl":"https://doi.org/10.15586/jkcvhl.v9i3.231","url":null,"abstract":"Over the last two decades, the treatment of metastatic RCC has changed significantly, and the role of surgery is being debated. A 50-year-old man presented with pain in his left loin. An ultrasound, followed by a CT scan, revealed a 17.5 cm left renal mass invading the left suprarenal gland, spleen, and pancreatic tail. Radical nephrectomy through chevron incision under epidural block with general anesthesia was performed. The entire mass was removed en bloc. The estimated blood loss was 300 mL, and no blood transfusions were performed. The operation took approximately 2 h. Histological examination revealed clear cell renal carcinoma with extension into the spleen, pancreatic tail, and diaphragmatic fibers with negative resection margin. The patient discharged after a 3-day uneventful hospital stay. Aggressive surgical removal of a locally invasive renal cell carcinoma is feasible and should be considered in patients with good performance status and no or minimal distant metastases.","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":" ","pages":"1-4"},"PeriodicalIF":1.6,"publicationDate":"2022-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40346732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary Leiomyomatosis and Renal Cell Cancer 遗传性平滑肌瘤病与肾细胞癌症

IF 1.6

Journal of Kidney Cancer and VHL Pub Date : 2022-05-26 DOI: 10.1007/978-3-642-16483-5_2682

Catarina Machado, Maria Sofia Quental, J. R. Brandão, M. Silva‐Ramos

引用次数: 0